Constellation Software Inc. Announces Annual Interest Rate for Series 1 Debentures
TORONTO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU, TSX: CSU.DB) (the "Company") announced today that the interest rate applicable to the unsecured subordinated floating rate debentures, Series 1 of the Company (the "Debentures") will be reset to 13.3% per annum on March 31, 2023. This new interest rate is equal to the annual average percentage change in the "All-items Consumer Price Index" published by Statistics Canada during the 12 month period ending on December 31, 2022 plus 6.5% and will be reflected in the June 30, 2023 interest payment on the Debentures.
The current interest rate of 9.9% will remain in place until March 30, 2023. The interest rate applicable to the Debentures will continue to be reset on an annual basis on March 31 of each year.
Further details regarding the Debentures can be found in the final short form prospectus of the Company dated April 17, 2015 which has been filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
About Constellation Software Inc.
Constellation Software acquires, manages and builds vertical market software businesses that provide mission-critical software solutions.
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...